First Patient in BARBICAN Study

orange__line
Back to NEWS

We are very pleased to announce that the first two Spanish patients have been successfully randomized in the Study by Dr. Viñas and her team from Hospital Josep Trueta (ICO) last June and have started treatment in the study.

The BARBICAN study compares the addition of ipatasertib to atezolizumab plus neoadjuvant chemotherapy in patients with triple-negative breast cancer. The primary clinical endpoint is to compare pCR rates in the two treatment arms and determine whether adding the AKT-inhibitor ipatasertib to atezolizumab and chemotherapy increases the probability of immune response over adding atezolizumab alone. In addition, a biological co-primary endpoint would determine whether adding the AKT-inhibitor ipatasertib to atezolizumab and chemotherapy increases the probability of immune response over adding atezolizumab to chemotherapy in all treated patients.

Globally, the trial will enroll a total of 142 patients in three countries, (UK, Germany, and Spain) with an estimated accrual period of 12 months.

We would like to thank all the study teams for their interest and commitment in the study.


Share (and comment) this content

Back to NEWS